New narcolepsy drug aims to keep patients awake and strong
NCT ID NCT07540364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called samelisant in 240 people with narcolepsy (with or without cataplexy). The goal is to see if it reduces excessive daytime sleepiness and sudden muscle weakness episodes over 12 weeks. Participants will take the drug or a placebo and report their sleepiness levels and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Do current sleepiness tests work for kids? a new study puts them to the test
- Zapping the Brain's deep centers: a new approach to narcolepsy?
- New test could sharpen diagnosis of narcolepsy and related sleep disorders
- New pill aims to tame Narcolepsy's sleep attacks and sudden muscle weakness
- Dream control: a new behavioral approach to tame narcolepsy nightmares
- New drug TAK-360 tested for Long-Term safety in sleep disorders